Samples from more than 2,300 pregnant patients will be evaluated to support commercialization of the Company's new maternal blood test targeted for use at 10-12 weeks of pregnancy; information at this early time point provides actionable results to the...
Read More »NX Prenatal Study Identifies Novel Proteomic Biomarkers of Spontaneous Preterm Birth from Serum-Derived Microparticles
LOUISVILLE, Ky., June 18, 2015 /PRNewswire/ — NX Prenatal Inc., a privately held women’s healthcare molecular diagnostic company, announced today that the American Journal of Perinatology has published the results of a blinded, retrospective study of 48 asymptomatic, healthy pregnant women ...
Read More »